In the past week, IOVA stock has gone up by 14.71%, with a monthly gain of 2.03% and a quarterly plunge of -43.84%. The volatility ratio for the week is 8.88%, and the volatility levels for the last 30 days are 9.49% for Iovance Biotherapeutics Inc. The simple moving average for the past 20 days is 8.74% for IOVA’s stock, with a -53.86% simple moving average for the past 200 days.
Is It Worth Investing in Iovance Biotherapeutics Inc (NASDAQ: IOVA) Right Now?
The 36-month beta value for IOVA is also noteworthy at 1.06. There are mixed opinions on the stock, with 8 analysts rating it as a “buy,” 4 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for IOVA is 265.54M, and at present, short sellers hold a 26.88% of that float. The average trading volume of IOVA on April 28, 2025 was 9.68M shares.
IOVA) stock’s latest price update
Iovance Biotherapeutics Inc (NASDAQ: IOVA)’s stock price has gone rise by 4.46 in comparison to its previous close of 3.36, however, the company has experienced a 14.71% increase in its stock price over the last five trading days. globenewswire.com reported 2025-04-23 that SAN CARLOS, Calif., April 23, 2025 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, announced that pre-clinical data for IOV-5001, a genetically engineered, inducible, and tethered interleukin-12 (IL-12) TIL cell therapy, will be presented at the 2025 AACR Annual Meeting. In addition, five-year outcomes data from the C-144-01 study of lifileucel monotherapy in patients with advanced melanoma, and a poster on study design for lifileucel in frontline advanced non-small cell lung cancer, will be presented at the 2025 ASCO Annual Meeting.
Analysts’ Opinion of IOVA
Many brokerage firms have already submitted their reports for IOVA stocks, with UBS repeating the rating for IOVA by listing it as a “Buy.” The predicted price for IOVA in the upcoming period, according to UBS is $17 based on the research report published on October 24, 2024 of the previous year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see IOVA reach a price target of $10, previously predicting the price at $19. The rating they have provided for IOVA stocks is “Neutral” according to the report published on July 29th, 2024.
Goldman gave a rating of “Buy” to IOVA, setting the target price at $12 in the report published on November 20th of the previous year.
IOVA Trading at -9.54% from the 50-Day Moving Average
After a stumble in the market that brought IOVA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -75.33% of loss for the given period.
Volatility was left at 9.49%, however, over the last 30 days, the volatility rate increased by 8.88%, as shares sank -3.31% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -34.27% lower at present.
During the last 5 trading sessions, IOVA rose by +14.71%, which changed the moving average for the period of 200-days by -53.45% in comparison to the 20-day moving average, which settled at $3.23. In addition, Iovance Biotherapeutics Inc saw -52.57% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IOVA starting from Maynard Ryan D, who sale 50,000 shares at the price of $10.06 back on Nov 12 ’24. After this action, Maynard Ryan D now owns 7,500 shares of Iovance Biotherapeutics Inc, valued at $503,000 using the latest closing price.
Maynard Ryan D, the Director of Iovance Biotherapeutics Inc, proposed sale 50,000 shares at $10.06 during a trade that took place back on Nov 12 ’24, which means that Maynard Ryan D is holding shares at $503,104 based on the most recent closing price.
Stock Fundamentals for IOVA
Current profitability levels for the company are sitting at:
- -2.41 for the present operating margin
- 0.18 for the gross margin
The net margin for Iovance Biotherapeutics Inc stands at -2.27. The total capital return value is set at -0.5. Equity return is now at value -57.48, with -44.02 for asset returns.
Based on Iovance Biotherapeutics Inc (IOVA), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -6.06.
Currently, EBITDA for the company is -395.28 million with net debt to EBITDA at 0.16. When we switch over and look at the enterprise to sales, we see a ratio of 6.66. The receivables turnover for the company is 2.37for trailing twelve months and the total asset turnover is 0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.74.
Conclusion
In summary, Iovance Biotherapeutics Inc (IOVA) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
